Table 1.
Pharmacokinetic parameters
| Parameter | Fenofibrate powder | PVP nanospheres | HP-β-CD nanocorpuscles | Gelatin nanocapsules |
|---|---|---|---|---|
| AUC (h μg/mL) | 17.72±1.52 | 61.01±14.66* | 42.59±11.55* | 96.80±15.42*,# |
| Cmax (μg/mL) | 2.36±0.34 | 6.73±1.75* | 6.46±1.83* | 9.14±2.47* |
| Tmax (hours) | 1.58±0.20 | 2.67±1.03 | 1.25±0.27* | 1.75±0.27 |
| t1/2 (hours) | 6.08±0.92 | 6.70±0.28 | 5.29±0.78 | 6.17±0.58 |
| Kel (hour−1) | 0.12±0.02 | 0.10±0.004 | 0.13±0.02 | 0.11±0.01 |
| MRT (hours) | 7.41±0.50 | 7.95±0.08 | 6.65±0.31 | 7.91±0.21 |
Notes: Each value indicates the mean ± SD (n=6).
*
P<0.05 compared with fenofibrate powder.
#
P<0.05 compared with other nanoparticulated formulations.
Abbreviations: PVP, polyvinylpyrrolidone; HP-β-CD, hydroxypropyl-β-cyclodextrin; SD, standard deviation; AUC, area under the curve; t1/2, half-life; Kel, elimination rate constant; MRT, mean residence time.